EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vaccinex's enterprise value is $7.48 Mil.
Vaccinex's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.57 Mil. Therefore, Vaccinex's EV-to-Revenue for today is 13.13.
The historical rank and industry rank for Vaccinex's EV-to-Revenue or its related term are showing as below:
VCNX'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.33 Med: 112.38 Max: 2644.57
Current: 13.13
During the past 8 years, the highest EV-to-Revenue of Vaccinex was 2644.57. The lowest was 3.33. And the median was 112.38.
VCNX's EV-to-Revenue is ranked worse than 60.5% of 1043
companies
in the Biotechnology industry
Industry Median: 8.03
vs VCNX: 13.13
As of today (2024-05-17), Vaccinex's stock price is $5.54.
Vaccinex's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.37. Therefore, Vaccinex's PS Ratio for today is 2.33.
Vaccinex EV-to-Revenue Historical Data
The historical data trend for Vaccinex's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vaccinex's EV-to-Revenue
For the Biotechnology subindustry, Vaccinex's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Vaccinex's EV-to-Revenue falls into.
Vaccinex's current Enterprise Value is $7.48 Mil.
Vaccinex's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex's share price for today is $5.54.
Vaccinex's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Vaccinex's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb. The firm generates revenue from collaborative research, license, development and commercialization agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 